Powered by

GNW: Novartis Kisqali significantly extends life in women with HR+/HER2-

Jun 01, 2019 - AWP OTS (Original Text Service)

advanced breast cancer in MONALEESA-7 trial

* Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1]

* After a median of 42 months follow-up, the survival rate was 70.2% for women who received Kisqali combination therapy compared to 46.0% for women who received endocrine therapy alone[1]

* Advanced breast cancer in premenopausal women is the leading cause of cancer death in women 259 years old[2],[3]

* MON...